Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: A Hoosier Oncology Group trial

Edgardo A. Faylona, Patrick J. Loehrer, Rafat Ansari, Alan B. Sandler, René Gonin, Lawrence H. Einhorn

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Purpose: The study was undertaken to determine the activity and toxicity of oral etoposide (VP-16), ifosfamide, and cisplatin combination chemotherapy for previously treated, recurrent small-cell lung cancer (SCLC). Patients and Methods: In this phase II trial, 46 patients were enrolled to receive oral VP-16, 37.5 mg/m2/d for 21 days, ifosfamide 1.2 g/m2/d for 4 days, and cisplatin 20 mg/m2/d for 4 days, with courses repeated every 28 days. Response, survival, and toxicity data were then noted. Results: Forty-two of 46 patients were assessable for response, survival, and toxicity. Thirty-six of 42 patients had received prior cisplatin plus VP-16. The first 22 patients received oral VP-16 for 21 days, but the subsequent 20 patients received oral VP-16 for 14 days after an interim analysis showed marked myelosuppression. Twenty-three of 42 patients (55%) had an objective response, with six complete responses (CRs; 14%), and 17 partial responses (PRs; 40%). The median progression-free survival time was 20 weeks (range, 2 to 66) and the overall median survival duration was 29 weeks (range, 1 to 76). Myelosuppression was significant, with six treatment-related deaths, four as a result of sepsis. Conclusion: The combination of oral VP-16, ifosfamide, and cisplatin is on active regimen in the treatment of recurrent SCLC. However, hematologic toxicity was severe in this pretreated patient population.

Original languageEnglish (US)
Pages (from-to)1209-1214
Number of pages6
JournalJournal of Clinical Oncology
Volume13
Issue number5
DOIs
StatePublished - May 1995

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of daily oral etoposide plus ifosfamide plus cisplatin for previously treated recurrent small-cell lung cancer: A Hoosier Oncology Group trial'. Together they form a unique fingerprint.

  • Cite this